1. Blazar BR, et al. Nat Rev Immunol. 2012;12(6):443-458.
The Science Behind GVHD
GVHD is a major cause of death after allogeneic transplantation
For many patients with blood cancers, allo-HSCT represents the only possibility of a cure.1
1. Blazar BR, et al. Nat Rev
Immunol.
2012;12(6):443-458.
While the primary cause of death post transplantation is relapse from primary disease, GVHD is a major source of morbidity and nonrelapse mortality in allo-HSCT recipients.2
2. McDonald-Hyman C, et al. Sci Transl Med. 2015;7(280):280rv2. doi:10.1126 /scitranslmed.aaa6853.
2. McDonald-Hyman C, et al. Sci Transl Med.
2015;7(280):280rv2.
doi:10.1126/ scitranslmed.aaa6853.
Post-transplantation mortality rates due to GVHD are similar for recipients of MRD and MUD transplants.3
3. D'Souza A, et al. Biol Blood Marrow Transplant. 2017;23(9):1417-1421.
3. D'Souza A, et al. Biol Blood
Marrow Transplant.
2017;23(9):1417-1421.
Expert Video Series: Early Identification and Assessment of Chronic GVHD
In this four-part video series, Linda M. Perry, MS, PA-C, University of Pennsylvania, shares her clinical perspective on the need to identify the early signs and symptoms of chronic GVHD across all organ systems.
Assessing Your Patients With Acute GVHD
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; GVHD, graft-versus-host disease; MRD, matched related donor; MUD, matched unrelated donor.